TrialDiabetes, obesity & metabolism2026

Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.

Masashi Shimoda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.